Welcome to BioSeeker Group!

Viral Carcinogenesis Drug Pipeline Update

Additional Information

Published Date Aug 4, 2016
Format Desktop App plus Online Access to Updates (One Year)
Publisher BioSeeker Group
Product Line View All Available Drug Pipeline Update Reports

Availability: In stock

$2,250.00

Quick Overview

BioSeeker Group have identified 246 companies plus partners who are today developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer across 169 different targets. In addition, there is 1 suspended drug and another 138 drugs where development has been ceased.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Viral Carcinogenesis Drug Pipeline Update.

    To find out more about Viral Carcinogenesis Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Viral Carcinogenesis Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or
Extra value: One year of free online updates included with this product

Executive Summary

BioSeeker Group have identified 246 companies plus partners who are today developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer across 169 different targets. In addition, there is 1 suspended drug and another 138 drugs where development has been ceased.

For busy executives within Pharma, Biotech and Investment companies who know they need to stay on top of the developmental environment in their field, we offer the Drug Pipeline update series.

You get detailed, world-wide drug pipeline information, delivered in an unbiased and independent pipeline progress analysis for each identified drug.

Buying the Viral Carcinogenesis Drug Pipeline Update will mean you have this important data at your fingertips and ensure that you can:

* Show investors/board/management that you are right on top of drug development progress in your therapeutic area.
* Find competitors, collaborations partners, M&A candidates etc. and track them by their products.
* Jump start competitive drug intelligence operations
* Benchmark your own development against world wide data
* Compare portfolio and therapy focus with your peers
* Speed up pro-active in-/outlicensing strategy work

Our software lets you define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.


The following short video playlist demonstrates the use of the filter sections, how you can make an inclusion and exclusion search and what to expect from a drug profile result.


Some facts about Viral Carcinogenesis Drug Pipeline Update

There is a strong association between viruses and the development of human malignancies. We now know that at least six human viruses, Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1) and Kaposi's associated sarcoma virus (KSHV) contribute to 10-15% of the cancers worldwide. Via expression of many potent oncoproteins, these tumor viruses promote an aberrant cell-proliferation via modulating cellular cell-signaling pathways and escape from cellular defense system such as blocking apoptosis. Human tumor virus oncoproteins can also disrupt pathways that are necessary for the maintenance of the integrity of host cellular genome. Viruses that encode such activities can contribute to initiation as well as progression of human cancers.
There are today 246 companies plus partners developing 311 viral carcinogenesis targeting drugs in 1170 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 138 drugs. Viral Carcinogenesis Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 169 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 164 out of the 166 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 37 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.


Details from Viral Carcinogenesis Drug Pipeline Update at a glance

This short overview shows actual findings from the Viral Carcinogenesis Drug Pipeline Update report.

Companies Includes more than 246 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms Lists commercial, generic and code names for drugs.
Developmental stage This Drug Pipeline Update contains 311 viral carcinogenesis targeting drugs in development, which have a total of 1170 developmental projects in cancer. In addition there are suspended and ceased drugs.

Pipeline Breakdown According to Number of Drugs
Marketed# 19
Pre-registration# 2
Phase III# 24
Phase II# 104
Phase I# 119
Preclinical# 151
No Data# 7
Suspended# 1
Ceased# 138

Note: You are able to sort and find drugs according to developmental stage from drop-down menu in the application.
Indications Included viral carcinogenesis targeting drugs are also in development for 176 other indications, where of 123 are different cancer indications.

Note: You are able to find and sort drugs according to type of indication from drop-down menu in the application.
Targets Mutations
All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 164 out of the 166 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures
The identity of available biological structures on 136 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 3430 structures available today among drug targets.

Identified drugs are linked to more than 169 different targets, divided into 37 classifications of molecular function:
- Antigen binding
- Catalytic activity
- Cell adhesion molecule activity
- Chaperone activity
- Chemokine activity
- Chromatin binding
- Cysteine-type peptidase activity
- Deacetylase activity
- DNA binding
- DNA topoisomerase activity
- DNA-directed DNA polymerase activity
- G-protein coupled receptor activity
- GTPase activity
- Kinase activity
- Kinase binding
- Kinase regulator activity
- Lipid kinase activity
- Metallopeptidase activity
- MHC class I receptor activity
- Molecular function unknown
- Protein binding
- Protein serine/threonine kinase activity
- Protein threonine/tyrosine kinase activity
- Protein tyrosine/serine/threonine phosphatase activity
- Protein-tyrosine kinase activity
- Receptor activity
- Receptor signaling complex scaffold activity
- Receptor signaling protein serine/threonine kinase activity
- RNA-directed DNA polymerase activity
- Superoxide dismutase activity
- Transcription factor activity
- Transcription regulator activity
- Transmembrane receptor activity
- Transmembrane receptor protein tyrosine kinase activity
- Transporter activity
- Ubiquitin-specific protease activity
- Voltage-gated ion channel activity

Sub-Cellular Localization
Identified targets are categorized into 27 different primary and alternate sub-cellular localizations:
- Basolateral membrane
- Cell junction
- Centrosome
- Chromosome
- Clathrin-coated vesicle
- Cytoplasm
- Cytoplasmic vesicle
- Cytoskeleton
- Cytosol
- Endoplasmic reticulum
- Endosome
- Extracellular
- Extracellular matrix
- Golgi apparatus
- Integral to membrane
- Lysosome
- Mitochondrial membrane
- Mitochondrion
- Nuclear membrane
- Nucleolus
- Nucleus
- Perinuclear region
- Perinuclear vesicle
- Peroxisome
- Plasma membrane
- Secretory granule
- Secretory vesicle

Note: You are able to find and sort drugs according to target gene name, protein name, molecular function of target, target localization, presence of mutations and availability of biological structures of target from drop-down menus in the application.
Target Expression Profile Direct links are provided from inside the application to 268 protein expression profiles of 157 drug targets in various human tissues and cancer types, cell lines and primary cells, including up to:
- 48 different normal tissue types
- 20 different types of cancer
- 47 cell lines
- 12 samples of primary blood cells
Pathway Referals Identified targets have been cross referenced against their involvement in different cellular pathways, according to BioCarta, KEGG, NCI-Nature and NetPath.
- BioCarta# 226 Pathways
- KEGG# 159 Pathways
- NCI-Nature# 243 Pathways
- NetPath# 32 Pathways

Note: You are able to find and sort drugs according to targeted pathways from drop-down menus in the application.
Mechanism In total there are different drug mechanism of action represented in this Drug Pipeline Update.

Note: You are able to find and sort drugs according to mechanism of action from drop-down menu in the application.
Compound Identified drug compounds are described by:

Compound type, Chemical name, CAS Number and molecular weight

Note: You are able to sort and find drugs according to compound type from drop-down menu in the application.


The Drug Profiles: Progress analysis and review of drug development.

Viral Carcinogenesis Drug Pipeline Update provides you with a profile for each identified drug.
Click here for a short video (6m 12s) showing a typical drug profile

A typical drug profile reports on, depending on stage of development and available information:

Drug Name & SynonymsPresentation of drug name and synonyms.
Principal Company & Partners Presentation of principal Company and partners.
Target and Molecular Function of Target Described target(s) is/are presented with: Official Gene Symbol – Chromosome Location – Gene & Protein Name – Molecular Function
Target Localization Described target(s) is/are presented with primary and alternate localizations.
Target Expression Profiles
Links to protein expression profile(s) of target(s) in various human tissues, cell lines and primary cells, including up to:
48 different normal tissue types
20 different types of cancer
47 cell lines
12 samples of primary blood cells
Mutation All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers.
Biological Structures The identity of available biological structures on drug targets was retrieved from the RCSB Protein Databank for you to easily review what available structures of drug targets exist.
Targeted Pathways Described target(s) is/are matched for the involvement in cellular pathways according to BioCarta, KEGG, NCI-Nature and NetPath.
Mechanism Drug mechanism of action
Developmental Projects Summary field of developmental projects for the drug, including indication, developmental stage and status.
Example:
Cancer, myeloma – Phase II Clinical Trial – Active
Cancer, prostate – Phase III Clinical Trial – Ceased
Drug Description Short introduction to drug
Compound Data Compound type, Chemical name, CAS Number and molecular weight.
Patent Data Available patent information related to the drug is presented here.
Fillings and Approvals Approvals and submissions
Analyst comments
Deals and Licensing Collaborations and deals
Availability for licensing
Phase IV Data Available Phase IV development data, developmental history and scientific data.
Phase III Data Available Phase III development data, developmental history and scientific data.
Phase II Data Available Phase II development data, developmental history and scientific data.
Phase I Data Available Phase I development data, developmental history and scientific data.
Phase 0 Data Available Phase 0 development data, developmental history and scientific data.
Preclinical Data Available Preclinical data, developmental history and scientific data.
Discovery Data Available discovery development data, developmental history and scientific data., developmental history and scientific data.


About the unique Drug Pipeline Update Software Application

After purchase, the Drug Pipeline Update is delivered to you via electronic download in a powerful yet easy to use desktop application which requires no installation.

Find and sort drugs by twenty-four different parameters, all of which can be used as inclusion or exclusion parameters, plus free text search field. Our dynamic report generator lets you easily and quickly generate HTML drug profile reports directly in your web browser, whether it is a single drug profile or your own report of a selection of drugs that match your criteria.


Application Features Search, Find and Filter Panel with Initial Result Presentation
With this panel you can define your selectivity in each drug search with up to 24 different drug specific parameters. Each parameter has multi-select options to them and can be used as either an inclusion parameter or exclusion parameter.
Click here for a short video (2m 14s) showing an overview of the filters.

The initial result table is a dynamic sortable table which gives you a fast overview of found results and can be narrowed down further by your own additional keywords.
Click here for a short video (3m 26s) showing an example of an inclusion and exclusion search to create the initial results table.

Direct linkage from inside the application to related internet resources
- Drug data is linked to search engines like Google and PubMed
- Drug target data is linked directly to BioCarta, Human Protein Atlas, KEGG, NCI-Nature, NetPath etc.
- Direct links to company web pages of companies

Dynamic Report Generator
Our dynamic report generator lets you with ease and speed generate html reports directly in your web browser (Internet Explorer and FireFox), whether it is a single drug profile or an entire search you want have a report of.
Click here for a short video (6m12s) showing a typical drug profile

System Requirements - Operating system: Windows (2000/XP/Vista/7) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Viral Carcinogenesis Drug Pipeline Update.
    To find out more about Viral Carcinogenesis Drug Pipeline Update, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Viral Carcinogenesis Drug Pipeline Update is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Drugs' category:


Target Atlas in Gastrointestinal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Wnt Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 228 companies plus partners who are today developing 253 Wnt pathway targeting drugs in 935 developmental projects in cancer across 204 different targets. In addition, there are 2 suspended drugs and another 118 drugs where development has been ceased. Learn More

Other selected research from the 'Drug Pipeline Updates' category:


Gene Therapy in Oncology Drug Pipeline Update
BioSeeker Group have identified 125 companies plus partners who are today developing 103 gene therapy drugs in 262 developmental projects in cancer across 107 different targets. In addition, there are 4 suspended drugs and another 105 drugs where development has been ceased. Learn More


Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update
BioSeeker Group have identified 238 companies plus partners who are today developing 301 Toll-like Receptor signaling pathway targeting drugs in 996 developmental projects in cancer across 177 different targets. In addition, there are 6 suspended drugs and another 110 drugs where development has been ceased. Learn More

Other selected research from the 'R&D' category:


Target Atlas in Gastrointestinal Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


TCR/CAR-T Therapies in Oncology Drug Pipeline Update
BioSeeker Group have identified 40 companies plus partners who are today developing 124 TCR/CAR-T drugs in 300 developmental projects in cancer across 58 different targets. In addition, there is 1 suspended drug and another 1 drugs where development has been ceased. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Ovarian Cancer: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline
This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. Learn More